Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients

Autor:	Wing Y. Au, Clarence C.K. Lam, Eric Tse, Yok L. Kwong, Shing Y. Ma, Anskar Y.H. Leung, Chor S. Chim, Albert K. W. Lie, Raymond Liang
Rok vydání:	2004
Předmět:	medicine.medical_specialty Mitoxantrone Pathology Hematology business.industry medicine.drug_class Lymphocyte Gastroenterology Antimetabolite Fludarabine Regimen medicine.anatomical_structure Internal medicine medicine Corticosteroid business Dexamethasone medicine.drug
Zdroj:	British Journal of Haematology. 124:754-761
ISSN:	0007-1048
DOI:	10.1111/j.1365-2141.2004.04852.x
Popis:	Summary The treatment results of indolent lymphoid malignancies in Chinese are poorly reported. The efficacy of FND (fludarabine 25 mg/m2/d, ×3; mitoxantrone 10 mg/m2/d, ×1; dexamethasone 20 mg/d, ×5; monthly cycles, ×6) in 95 Chinese patients with indolent B-cell malignancies (at diagnosis: 55, relapse/refractory disease: 40) and nine Chinese patients with T-cell large granular lymphocyte leukaemia (T-LGL leukaemia) (at diagnosis: two, refractory disease: seven) was evaluated. For B-cell malignancies, the complete response (CR), partial response (PR) and overall response (OR) rates were 50·5%, 18% and 68·5% respectively. Better results were obtained for primary versus relapse/refractory disease (CR: 60% vs. 37·5%, P = 0·03; OR: 84% vs. 47·5%, P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::909867a96988c92ead78c7f999fc6d4e https://doi.org/10.1111/j.1365-2141.2004.04852.x Zobrazit plný text záznamu Plný text